[{"id":"111dadaf-4e0e-41c4-96f3-ff25aabf637a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03047213","created_at":"2021-01-18T15:00:26.479Z","updated_at":"2025-02-25T15:17:24.811Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations","source_id_and_acronym":"NCT03047213","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TSC2 • TSC1","pipe":" | ","alterations":" TSC1 mutation • TSC2 mutation","tags":["TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 10/06/2020","primary_completion_date":" 10/06/2020","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2025-02-12"},{"id":"6f199ca7-66c7-422b-8786-948a1a709536","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213678","created_at":"2021-01-18T15:51:26.276Z","updated_at":"2024-07-02T16:35:02.372Z","phase":"Phase 2","brief_title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213678","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • TSC2 • TSC1","pipe":" | ","alterations":" PTEN expression • TSC1 mutation • TSC2 mutation","tags":["PTEN • TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression • TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-21"},{"id":"addcbe1a-f712-4fba-99e9-0e5ca8f68e89","acronym":"","url":"https://clinicaltrials.gov/study/NCT03649919","created_at":"2021-01-18T17:54:50.702Z","updated_at":"2024-07-02T16:36:26.506Z","phase":"","brief_title":"Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children","source_id_and_acronym":"NCT03649919","lead_sponsor":"Children's Hospital of Fudan University","biomarkers":" TSC2 • TSC1","pipe":" | ","alterations":" TSC1 mutation • TSC2 mutation • TSC1 deletion","tags":["TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSC1 mutation • TSC2 mutation • TSC1 deletion"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 10/30/2021","primary_completion_date":" 10/30/2021","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2021-08-11"},{"id":"c3d089ca-84d6-49af-9d8e-eb985fdd8f37","acronym":"","url":"https://clinicaltrials.gov/study/NCT02352844","created_at":"2021-01-18T11:11:41.931Z","updated_at":"2024-07-02T16:37:06.465Z","phase":"Phase 2","brief_title":"Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations","source_id_and_acronym":"NCT02352844","lead_sponsor":"Washington University School of Medicine","biomarkers":" STK11 • NF1 • TSC2 • TSC1","pipe":" | ","alterations":" NF1 mutation • TSC1 mutation • TSC2 mutation","tags":["STK11 • NF1 • TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation • TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/07/2015","start_date":" 10/07/2015","primary_txt":" Primary completion: 08/15/2017","primary_completion_date":" 08/15/2017","study_txt":" Completion: 08/15/2017","study_completion_date":" 08/15/2017","last_update_posted":"2018-10-02"},{"id":"4e9ede92-6285-4b0b-b009-176ccbfbc39c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03108261","created_at":"2021-01-18T15:18:47.515Z","updated_at":"2024-07-02T16:37:16.148Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations","source_id_and_acronym":"NCT03108261","lead_sponsor":"Yale University","biomarkers":" TSC2 • TSC1","pipe":" | ","alterations":" TSC1 mutation • TSC2 mutation","tags":["TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 209","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2017-11-21"}]